文献速递皮肤肿瘤

欧洲黑色素瘤疾病成本研究:建模方法

Cost-of-illness of melanoma in Europe - a modelling approach.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-01-01

本研究通过系统文献检索获取成本信息,对无成本数据国家建立基于GDP、卫生支出、GNI和流行病学数据的推算模型,并按购买力平价调整,比较欧洲各国黑色素瘤的疾病成本。

要点

  • 直接成本占比各国差异大,范围3%至26%。

核心结论

  • 黑色素瘤在欧洲造成显著疾病成本,各国人均成本差异大,早期干预和预防可能节约成本。

研究设计与样本

  • 基于系统文献检索的成本信息,对无数据国家建立推算模型,按购买力平价调整进行跨国比较。

主要发现

  • 直接成本占比各国为3%至26%。
  • 2004年后入盟国家治疗与发病率成本明显较低,高人均GDP国家死亡率成本较低。

临床怎么用

  • 提示各国应关注黑色素瘤的经济负担,早期干预和预防可能具有节约成本的潜力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Malignant melanoma is accounting for the vast majority of skin cancer death. The treatment and productivity loss due to morbidity or premature mortality are associated with costs for society. There are few cost-of-illness (COI) studies on malignant melanoma in European countries from societal perspective and currently there is no publication analysing the COI in all European countries. OBJECTIVES: The objective of the present study was to comparatively estimate COI of malignant melanoma in the European countries based on an identical approach. METHODS: Cost information was obtained from results of a systematic literature research. For countries with no available cost information, a model for imputation of cost data was developed. Country-specific costs were modelled on the national gross domestic product, health expenditures, gross national income and epidemiological data. The adjustment for purchasing power parity allowed a comparison across countries. RESULTS: Crude national costs of malignant melanoma ranged between € 1.1 million in Iceland and € 543.8 million in Germany and resulted in € 2.7 billion for all EU/EFTA states. Estimated crude costs per patient were lowest in Bulgaria (€ 6422) and highest in Luxembourg (€ 50 734). The share of direct costs varied from 3% to 26% across countries. After adjustment for the purchasing power parity costs per patient ranged between € 14 420 in Bulgaria and € 50 961 in Cyprus. Treatment expenses and morbidity costs were markedly lower for countries that entered the EU since 2004. By contrast, mortality costs were lower in countries with a high gross domestic product per capita. CONCLUSION: In this first estimation, malignant melanoma induces relevant COI in Europe. There was large variation in the costs per patient due to different health care systems and expenses. Beyond decreasing patient burden, early intervention and prevention of melanoma could have a relevant potential to save costs across Europe.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Krensel M, Schäfer I, Augustin M, et al. Cost-of-illness of melanoma in Europe - a modelling approach. J Eur Acad Dermatol Venereol. 2019. PMID: 30811699. doi:10.1111/jdv.15308

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。